Zymergen (ZY) Stock Price, News & Analysis

Company Overview

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.

Key Stats

• Today's Range: $2.43 to $2.43
• 50-Day Range: $2.35 to $3.14
• 52-Week Range: $1.10 to $12.42
• Volume: 85 shs
• Average Volume: 1.23 million shs
• Market Capitalization: $253.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZY Stock Analysis - Frequently Asked Questions

When did Zymergen IPO?

Zymergen (ZY) raised $401 million in an initial public offering on Thursday, April 22nd 2021. The company issued 13,600,000 shares at $28.00-$31.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen, UBS Investment Bank and Lazard served as the underwriters for the IPO.

What other stocks do shareholders of Zymergen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zymergen investors own include Tesla (TSLA), NIO (NIO), Meta Platforms (META), PayPal (PYPL), Snowflake (SNOW) and Teladoc Health (TDOC).

Company Calendar

• Today: 8/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Basic Materials
• Industry: Commercial physical research
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ZY
• CIK: 1645842
• Web: www.zymergen.com
• Phone: 415-801-8073
• Fax: N/A
• Employees: 502
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$361.79 million
• Net Margins: -2,508.94%
• Pretax Margin: -2,508.42%
• Return on Equity: -93.37%
• Return on Assets: -61.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.59
• Quick Ratio: 4.47

Sales & Book Value

• Annual Sales: $16.74 million
• Price / Sales: 15.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.99 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 104,355,000
• Free Float: 92,145,000
• Market Cap: $253.58 million
• Optionable: Not Optionable
• Beta: 1.69